Chronic rhinosinusitis with nasal polyps - Pipeline Insight, 2024

This “Chronic rhinosinusitis with nasal polyps - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Chronic rhinosinusitis with nasal polyps pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic rhinosinusitis with nasal polyps: Understanding

Chronic rhinosinusitis with nasal polyps: Overview

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition affecting the nasal passages and sinuses, characterized by the growth of benign polyps. These polyps, which are soft, painless, and non-cancerous, arise from the mucous membranes and can obstruct the nasal airways, leading to significant breathing difficulties. Patients often experience symptoms such as nasal congestion, a reduced sense of smell, facial pain or pressure, and nasal discharge. The condition is distinct from other forms of chronic rhinosinusitis due to the presence of these polyps, which play a critical role in the chronic nature and severity of the disease.

The etiology of CRSwNP is multifactorial, involving a combination of genetic predisposition, environmental factors, and immune system dysfunction. Chronic inflammation is a hallmark of the disease, often driven by a skewed immune response favoring Type 2 inflammation, which involves cytokines such as IL-4, IL-5, and IL-13. This inflammatory pathway leads to tissue remodeling and polyp formation. Additionally, CRSwNP is commonly associated with other conditions like asthma, aspirin-exacerbated respiratory disease (AERD), and allergic rhinitis, indicating a broader systemic involvement. This association often complicates the management of the disease, as patients may present with a spectrum of symptoms and comorbidities requiring comprehensive treatment strategies.

Treatment for CRSwNP typically involves a combination of medical and surgical approaches aimed at reducing inflammation, shrinking polyps, and improving sinus drainage. First-line treatments often include intranasal corticosteroids to reduce local inflammation and polyp size. In more severe cases, systemic corticosteroids or biologic therapies targeting specific inflammatory pathways may be employed. Surgical intervention, such as functional endoscopic sinus surgery (FESS), is considered when medical management fails to provide relief. This procedure involves removing polyps and improving sinus drainage pathways, which can significantly enhance the quality of life for affected individuals. Ongoing research into the underlying mechanisms of CRSwNP continues to drive the development of more targeted and effective therapies.

"Chronic rhinosinusitis with nasal polyps- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic rhinosinusitis with nasal polyps pipeline landscape is provided which includes the disease overview and Chronic rhinosinusitis with nasal polyps treatment guidelines. The assessment part of the report embraces, in depth Chronic rhinosinusitis with nasal polyps commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic rhinosinusitis with nasal polyps collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic rhinosinusitis with nasal polyps R&D. The therapies under development are focused on novel approaches to treat/improve Chronic rhinosinusitis with nasal polyps.

Chronic rhinosinusitis with nasal polyps Emerging Drugs Chapters

This segment of the Chronic rhinosinusitis with nasal polyps report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic rhinosinusitis with nasal polyps Emerging Drugs

GSK3511294: GlaxoSmithKline

GSK3511294 (depemokimab) is a novel investigational treatment being studied for chronic rhinosinusitis with nasal polyps (CRSwNP). Depemokimab is thought to work by inhibiting interleukin-5 (IL-5), a key cytokine involved in the type 2 inflammatory response that drives eosinophilic inflammation in CRSwNP. Blocking IL-5 may help reduce polyp size and improve symptoms. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Chronic rhinosinusitis with nasal polyps.

CM326: Keymed Biosciences Co.Ltd

CM326 is a monoclonal antibody being investigated for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The rationale for targeting thymic stromal lymphopoietin (TSLP) with CM326 is based on its role in the pathogenesis of CRSwNP. TSLP is a key cytokine involved in the initiation and maintenance of type 2 inflammatory responses, which are characteristic of CRSwNP. Currently, the drug is in the Phase II stage of development to treat Chronic rhinosinusitis with nasal polyps.

Chronic rhinosinusitis with nasal polyps: Therapeutic Assessment

This segment of the report provides insights about the different Chronic rhinosinusitis with nasal polyps drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic rhinosinusitis with nasal polyps

• There are approx. 8+ key companies which are developing the therapies for Chronic rhinosinusitis with nasal polyps. The companies which have their Chronic rhinosinusitis with nasal polyps drug candidates in the most advanced stage, i.e. Phase III include, GlaxoSmithKline.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Chronic rhinosinusitis with nasal polyps pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic rhinosinusitis with nasal polyps: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic rhinosinusitis with nasal polyps therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic rhinosinusitis with nasal polyps drugs.

Chronic rhinosinusitis with nasal polyps Report Insights

• Chronic rhinosinusitis with nasal polyps Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic rhinosinusitis with nasal polyps Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic rhinosinusitis with nasal polyps drugs?
• How many Chronic rhinosinusitis with nasal polyps drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic rhinosinusitis with nasal polyps?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic rhinosinusitis with nasal polyps therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic rhinosinusitis with nasal polyps and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Keymed Biosciences Co.Ltd
• GlaxoSmithKline
• Genrix (Shanghai) Biopharmaceutical Co., Ltd.
• Guangdong Hengrui Pharmaceutical Co., Ltd

Key Products

• CM326
• GSK3511294
• GR1802
• SHR-1905

Please note: The report will be dispatched within 2-3 days